InvestSMART

Living Cell Technologies Limited (ASX: LCT) - Announcements

- Current share price for LCT : $0.014

ASX company news and announcements for Living Cell Technologies Limited (LCT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Living Cell Technologies Limited (LCT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Living Cell Technologies Limited (LCT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Living Cell Technologies Limited (LCT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$23 International foundations team up to fund LCT NZ Trial 16 Feb 2011 9:14AM $0.120 $0.014 fallen by 88.33%
$23 Share Placement with ASK 31 Jan 2011 8:40AM $0.130 $0.014 fallen by 89.23%
$23 Appendix 4C - quarterly 28 Jan 2011 10:22AM $0.084 $0.014 fallen by 83.33%
$23 LCT Completes First Closing on Funding 4 Jan 2011 12:00PM $0.125 $0.014 fallen by 88.80%
$23 LCT executes $5.75m funding agreement 31 Dec 2010 9:46AM $0.135 $0.014 fallen by 89.63%
$23 LCT Negotiating Funding 23 Dec 2010 1:03PM $0.125 $0.014 fallen by 88.80%
$23 LCT Approved to Further Expand DIABECELL NZ Trial 20 Dec 2010 12:07PM $0.140 $0.014 fallen by 90%
$23 LCT`s DiabeCell Registered for Sale and Use in Russia 10 Dec 2010 9:01AM $0.170 $0.014 fallen by 91.76%
$23 Lifting of Trading Halt 18 Nov 2010 4:36PM $0.185 $0.014 fallen by 92.43%
$23 Trading Halt 18 Nov 2010 9:51AM $0.185 $0.014 fallen by 92.43%
$23 Promising Preclinical Results with NTCELL in Parkinsons 10 Nov 2010 10:27AM $0.195 $0.014 fallen by 92.82%
$23 Appendix 4C - quarterly 29 Oct 2010 1:47PM $0.125 $0.014 fallen by 88.80%
$23 LCT reports sustained improvement from DIABECELL NZ Trial 27 Oct 2010 11:09AM $0.165 $0.014 fallen by 91.52%
$23 LCT Restructures Executive Team for Commercial Focus 23 Sep 2010 9:05AM $0.175 $0.014 fallen by 92%
$23 Appendix 4E - Preliminary Final Report 27 Aug 2010 2:06PM $0.180 $0.014 fallen by 92.22%
$23 LCT receives approval to expand DIABECELL NZ Trial 4 Aug 2010 8:46AM $0.225 $0.014 fallen by 93.78%
$23 Appendix 4C - quarterly 30 Jul 2010 9:13AM $0.210 $0.014 fallen by 93.33%
$23 LCT reports consistent benefit in DIABECELL NZ Trial 13 Jul 2010 9:04AM $0.200 $0.014 fallen by 93%
$23 LCT Options underwritten 22 Jun 2010 9:08AM $0.230 $0.014 fallen by 93.91%
$23 Appendix 4C 29 Apr 2010 9:34AM $0.340 $0.014 fallen by 95.88%
$23 LCT receives grant from Juvenile Diabetes Research Foundn 27 Apr 2010 8:36AM $0.320 $0.014 fallen by 95.63%
$23 Report from LCTs Russian Phase I / IIa Diabetes Trial 7 Apr 2010 10:27AM $0.300 $0.014 fallen by 95.33%
$23 LCT Phase II Diabetes Trial Success - Approval to Progress 30 Mar 2010 9:47AM $0.245 $0.014 fallen by 94.29%
$23 Response to ASX Price Query 17 Mar 2010 4:50PM $0.255 $0.014 fallen by 94.51%
$23 Russia registers LCT encapsulation delivery device 10 Mar 2010 8:56AM $0.165 $0.014 fallen by 91.52%

451 - 475 of 584 results

Page 19 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.